AHCCCS
Pharmacy and Therapeutics Committee Meeting Minutes
April 13, 2017
12:00PM- 5:00 PM
701 E. Jefferson Phoenix, AZ  85034- Gold Room- 3rd Floor

Members Present:
Dan Lindell
Suzanne Campbell
Berkely McMurray
Cindy Komar
Stephen Chakmakian
Kathleen Bryant
Lydia Nesemann
Gloria Abril
Shawn McMahon
Joanna Kowalik
Suzanne Campbell

AHCCCS Staff:
Sara Salek
Suzi Berman
Robin Davis
Lauren Prole

Magellan Medicaid Admin:
Sarah Martinez
Christopher Andrews

Members Absent:
James Hargrave
Robert Marotz
Mohamed Ramadan
Otto Uhrik
WELCOME AND INTRODUCTIONS: SARA SALEK, M.D., CHIEF MEDICAL OFFICER, AHCCCS

1. Dr. Sara Salek called the meeting to order at 12:05 PM and welcomed committee members, staff, and guest presenters.
   a. P&T Minutes from January 25, 2017 were reviewed.
      i. Motion made by Lydia to approve the meeting minutes.
      ii. Motion seconded by Kathleen Bryant
      iii. All committee members voted in favor of approving the minutes
      iv. No committee members opposed or abstained.

AHCCCS and Behavioral Health Drug Lists

SUPPLEMENTAL REBATE CLASS REVIEWS

1. Opiate Dependent Treatment
   a. Clinical review: Sarah Martinez: Provider Synergies
   b. Pharma Testimony:
      i. Suboxone Film - Nicholas Casale III, Indivior
      ii. Vivitrol - Deborah Profant, Alkermes
      iii. Zubsolv – Jake Nichols, Orexo Pharmaceuticals
   c. Public Testimony:
      i. Michael Sucher MD, Community Bridges

2. Hypoglycemics (Incretin Mimetics / Enhancers)
   a. Clinical review: Sarah Martinez: Provider Synergies
   b. Pharma Testimony:
      i. Adlyxin – Lorraine Perkins, Sanofi
      ii. Glyxambi - Nana Numapau, Boehringer Ingelheim
      iii. Victoza – Anthony Hoovler, Novo Nordisk
   c. Public Testimony: None

3. Hypoglycemics (Insulin & Related Agents)
   a. Clinical review: Sarah Martinez: Provider Synergies
   b. Pharma Testimony:
i. Levemir - *Anthony Hoovler, Novo Nordisk*
ii. Novolog - *Anthony Hoovler, Novo Nordisk*
iii. Soliqua - *Lorraine Perkins, Sanofi*
iv. Tresiba - *Anthony Hoovler, Novo Nordisk*
v. Xultophy - *Anthony Hoovler, Novo Nordisk*

c. Public Testimony: None

4. COPD Agents
   a. Clinical review: Sarah Martinez: Provider Synergies
   b. Pharma Testimony:
      i. Stiolto Respimat: *Nana Numapau, Boehringer Ingelheim*
      ii. Spiriva Respimat: *Nana Numapau, Boehringer Ingelheim*
   c. Public Testimony: None
   d. 

______________________________

Executive Session – Closed to the Public

______________________________

1. **Preferred Drug Recommendation to the AHCCCS Drug List and/or the AHCCCS Behavioral Health Drug List for the following classes.**

   a. Committee members voted unanimously to add the following to the AHCCCS Drug list as preferred products. No committee members opposed or abstained.
      i. **Opioid Dependent Treatment**
         1. Naloxone vial and syringe (solution for injection)
         2. Naltrexone Oral
         3. Naloxone nasal spray (Narcan)
         4. Naltrexone ER injectable suspension (Vivitrol)
         5. Buprenorphine/naloxone sublingual film (Suboxone)
            **Grandfather- Buprenorphine**
      
ii. **Hypoglycemics (Incretin Mimetics / Enhancers)**
   1. Janumet
   2. Janumet XR
   3. Januvia
   4. Jentadueto
   5. Tradjenta
   6. Byetta Pens
   7. Symlin Pens
   8. Victoza
   9. Kombiglyze XR (ADDED)
10. Onglyza (ADDED)
11. Bydureon vial (ADDED)
12. Bydureon pen (ADDED)

Grandfathering- yes
PA required

iii. Hypoglycemics (Insulin & Related Agents) – Table vote and decision for insulin to July meeting to allow updated utilization data to be reviewed.

iv. COPD Agents
   1. Ipratropium inhalation solution
   2. Ipratropium/albuterol inhalation solution
   3. Spiriva
   4. Atrovent HFA
   5. Combivent Respimat

Grandfather- NO

Long Acting Opioid Prior Authorization Exclusions Discussion- Sara Salek

1. AHCCCS received feedback from the oncology community stating prior authorization requirement on long acting opioids is a barrier to care for oncology patients with neoplasm related pain.
2. It was recommended to approach long acting opioids with the same exclusions currently in place for short acting opioids for the following conditions:
   i. Active oncology diagnosis with neoplasm related pain (or)
   ii. Hospice care (or)
   iii. End of life care (other than hospice)
3. The Prescriber must notify the pharmacy that the long-acting opioid prescription is for G89.3 (Neoplasm related pain) by writing the ICD-10 code on the hard copy prescription or communicating it telephonically, electronically or via fax to the pharmacy. The pharmacy staff must enter the diagnostic code in the prescription claim’s NCPDP field.
4. Committee members voted unanimously to remove pa requirements for the above conditions effective July 1, 2017. No committee members opposed or abstained.
Opioid 7-Day Quantity Limitation update- Sara Salek, AHCCCS

1. On October 24, 2016, Governor Doug Ducey issued Executive Order 2016-06 which limits the initial opioid prescription for adults as well as the initial and refill opioid prescriptions for children through the Arizona Health Care Cost Containment System (AHCCCS) and the Arizona Department of Administration (ADOA).

2. AHCCCS issued a draft policy for a two-week public comment period in December 2016 and subsequently held a stakeholder session on January 11, 2017.

BIOSIMILAR UPDATE - Basalgar Insulin

1. Basalgar Insulin
   a. Due to the cost differential, AHCCCS will continue to require the brand name, Lantus, to be the only and preferred glargine insulin product available on the AHCCCS Drug List.

NEW DRUG REVIEWS: NON-SUPPLEMENTAL REBATE CLASS: SUZI BERMAN

1. The following new drugs were reviewed for the Non-Supplemental Rebate Class
   a. Eucrisa- Crisaborole
      1. Recommendation is to not add Eucrisa to the AHCCCS Drug Lists because we have many other products that are efficacious and less costly. Eucrisa is available through prior authorization based on medical necessity.
         a. 11 committee members voted in favor of the recommendations.
         b. No committee members voted against the recommendations.
         c. No committee member abstained.
   b. Vemlidy- Tenofovir Alefenamide
      1. Recommendation is to not add this drug to the AHCCCS Drug List, there are other first line agents available that are more cost-effective. Vemlidy is available through prior authorization based on medical necessity.
         a. 11 committee members voted in favor of the recommendations.
         b. No committee members voted against the recommendations.
         c. No committee member abstained.
FLUORIDE, SUZI BERMAN, AHCCCS

1. Fluoride is not currently not listed on the AHCCCS Drug List
2. The AHCCCS Dental Director is requesting we add Fluoride oral tablets to the AHCCCS Drug List to ensure that it is provided when medically necessary.
3. Recommendation is to add Fluoride oral agents to the AHCCCS Drug list without prior authorization effective 7/1/2017.
   a. 11 committee members voted in favor of the recommendations.
   b. No committee members voted against the recommendations.
   c. No committee member abstained.

NEXT MEETING DATES

2017 Meeting Dates:
Monday, July 10, 2017,
Thursday October 12, 2017

ADJOURNMENT

The meeting adjourned at 3:00 PM.
Minutes recorded by Robin Davis

Suzi Berman, RPh
Suzi Berman, RPh
Director of Pharmacy Services

April 13, 2017
Date